Victor Grifols Deu
Director/Board Member chez GRIFOLS, S.A.
Fortune : 131 654 $ au 31/03/2024
Profil
Victor Grifols Deu is currently the Director at Grifols SA and the Director at Araclon Biotech SL.
He has a graduate degree from UCD Michael Smurfit Graduate School of Business and an undergraduate degree from Institut Químic De Sarrià.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GRIFOLS, S.A. CLASS A
0,00% | 31/12/2022 | 14 620 ( 0,00% ) | 131 654 $ | 31/03/2024 |
Postes actifs de Victor Grifols Deu
| Sociétés | Poste | Début |
|---|---|---|
| GRIFOLS, S.A. | Director/Board Member | 30/05/2016 |
Araclon Biotech SL
 Araclon Biotech SL Miscellaneous Commercial ServicesCommercial Services Araclon Biotech SL researches and develops therapies and diagnostic methods for Alzheimer’s disease. Its research areas include early diagnosis of Alzheimer’s disease; therapy for Alzheimer’s disease; development of a predictive test for the Alzheimer’s disease in asymptomatic individuals; and development of therapy for Parkinson’s disease. The company was founded on January 27, 2004 and is headquartered in Zaragoza, Spain. | Director/Board Member | - |
Formation de Victor Grifols Deu
| UCD Michael Smurfit Graduate School of Business | Graduate Degree |
| Institut Químic De Sarrià | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GRIFOLS, S.A. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Araclon Biotech SL
Araclon Biotech SL Miscellaneous Commercial ServicesCommercial Services Araclon Biotech SL researches and develops therapies and diagnostic methods for Alzheimer’s disease. Its research areas include early diagnosis of Alzheimer’s disease; therapy for Alzheimer’s disease; development of a predictive test for the Alzheimer’s disease in asymptomatic individuals; and development of therapy for Parkinson’s disease. The company was founded on January 27, 2004 and is headquartered in Zaragoza, Spain. | Commercial Services |
